肿瘤细胞治疗研究
英文原题：Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors.
前列腺特异性膜抗原（PSMA）是少数已成功转化为临床应用的生物标志物之一，可作为前列腺癌患者的诊疗一体化生物标志物。
前列腺特异性膜抗原（PSMA）是少数已成功转化为临床应用的生物标志物之一，可作为前列腺癌患者诊疗一体化标志物。在前列腺癌中，PSMA在肿瘤细胞膜上过表达，可作为尿素类小分子抑制剂或放射性同位素偶联抗体的有效干预靶点。有趣的是，在若干非前列腺癌中，PSMA表达似乎与肿瘤新生血管相关。这为靶向非前列腺癌血管系统的治疗提供了新的机会。本综述讨论PSMA及其作为血管靶向治疗靶点的潜力，包括放射性配体治疗、融合蛋白疫苗和CAR T细胞疗法。
Prostate-specific membrane antigen (PSMA) is one of the few biomarkers which has been successfully translated to the clinic as theranostic biomarker for patients with prostate cancer. In the context of prostate cancer, PSMA is overexpressed on the cell membrane of tumor cells, making it a viable target for interventions with urea-based small molecule inhibitors or antibodies conjugated to radioactive isotopes. Interestingly, in several non-prostatic cancers, expression of PSMA appears to be associated with the tumor neovasculature. This offers novel therapeutic opportunities for treatments targeting the vasculature in non-prostatic cancers. In this review, we discuss PSMA and its potential as target for vasculature-directed therapeutic approaches, including radioligand therapy, fusion protein vaccination and CAR T-cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
